It has found extensive clinical application in treating glucocorticoid-induced osteoporosis and a wide range of related bone metabolic disorders.[66] In osteoclast precursor cells, the receptor activator of nuclear factor-κB (RANK) and its ligand, RANKL, are essential for osteoclasts growth, proliferation, activation, and the processes of transcription and translation.[67,68] Osteoprotegerin (OPG), a decoy receptor for RANKL widely distributed across various tissues and organs, can impede RANK protein expression via multiple intracellular signaling pathways. The gene discussed is TNFSF11; the disease is metabolic bone disorder.